This trial is active, not recruiting.

Condition fungal infection
Sponsor Pfizer
Start date March 2016
End date June 2019
Trial size 200 participants
Trial identifier NCT02674685, A1501106


Examine the safety and effectiveness of Vfend [voriconazole] for prophylaxix use under general clinical practices.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment
time frame: Maximum 3 years

Secondary Outcomes

Number of Participants with Clinical Response of Cure at the Test-of-Cure (TOC) Visit
time frame: Maximum 3 years

Eligibility Criteria

All participants of any age.

Inclusion Criteria: - Patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). Exclusion Criteria: - Patients who have been previously enrolled in this study.

Additional Information

Official title Vfend Special Investigation For Prophylaxis
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Pfizer.